James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

How to Handle This Listless, Go-Nowhere Market Environment

Goldman Sachs says idiosyncratic risk is at low levels -- in short, that means stock-picking is practically like throwing darts right now. Here's what to do.

These Stocks Are in the Sweet Spot Right Now

Just like Jan and Peter Brady, mid-cap stocks are often overlooked thanks to their bigger and smaller brethren. Right now's the time to rectify that mistake.

Save the Date? Apple’s Q3 Earnings

Apple's earnings announcement is just two weeks away. But the best time to make a trade on AAPL might be nowhere near the July 24 report.

Shouldn’t Acquisitions Actually Be Worth It?

Microsoft just announced it was flushing $6.2 billion on its 2007 acquisition of aQuantive. Unfortunately, money-sucking deals like this are far from isolated.

Who Wins Ford’s Foreign/Domestic Tug-of-War?

Right now, the best bullish argument of all for Ford isn't even one you can directly quantify on a balance sheet or income statement.

What’s the Real Impact of Generic Drugs?

The danger of patent expirations for big pharma isn't new, but the amount of market share those brands are losing to generics as a result are not pretty.

Verizon vs. AT&T: Which Should You Buy?

Stodgy telecoms AT&T and Verizon both have had fantastic returns this year, but one looks prepped to start eating away at the other.

Tire Manufacturers Finally Ready to Roll

The shipping industry is busier and rubber prices are tanking, creating the perfect storm for tire manufacturers -- and their investors -- to make some money.

Who Fits Into Microsoft’s Surface Ecosystem?

If Microsoft's Surface tablet is able to get legs, a number of stocks not tickered MSFT could enjoy a bump, while others might suffer collateral damage.

5 of Pharma’s Most Disastrous Drug Approvals

These five exciting drug approvals now serve as warning stories about the potential pitfalls for investors trying to time a pharma stock buy.